Literature DB >> 528374

Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.

D Dantchev, M Paintrand, M Hayat, C Bourut, G Mathé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 528374     DOI： 10.7164/antibiotics.32.1085

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  21 in total

1.  Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors:  S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  4'-O-tetrahydropyranyl adriamycin (THP-ADM)-induced modifications of murine peritoneal macrophages.

Authors:  A Bravo-Cuellar; G Mathé; S Orbach-Arbouys
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Phase I study of pirarubicin.

Authors:  A A Miller; M E Scheulen; U R Kleeberg; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  (2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies.

Authors:  T Takagi; M Oguro
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.

Authors:  K Yamada; S Shirakawa; R Ohno; H Yamada; Y Hirota; K Ohara; K Yamagata; M Kobayashi; M Hirano; Y Ikeda
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

6.  Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.

Authors:  R Ohno; K Kimura; I Amaki; M Hirano; A Hoshino; Y Ikeda; I Kimura; M Kobayashi; K Konno; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin).

Authors:  M N Raber; R A Newman; K Lu; S Legha; C Gorski; R S Benjamin; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.

Authors:  S Naito; T Ueda; S Kotoh; J Kumazawa; K Itoh; K Sagiyama; T Omoto; S Andoh; Y Hasegawa; Y Fujisawa
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.

Authors:  H Iguchi; H Tone; T Ishikura; T Takeuchi; H Umezawa
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.

Authors:  M Ogawa; H Miyamoto; J Inigaki; N Horikoshi; K Ezaki; K Inoue; K Ikeda; N Usui; H Nakada
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.